Tregs form an "immunosuppressive ring" around solid tumors that is broken down during adoptive cell therapy and cyclophosphamide combination immunotherapy.

Cancer cell expression of the T-cell co-stimulatory molecule CD80, or treatment with agonistic antibodies targeting the T-cell co-stimulatory receptors OX-40 or 4-1BB, enhances the anti-tumor activity of FAK inhibition.

The safety and strong antitumor effects of GPC1-specific CAR-T cells against GPC1-expressing solid tumors were demonstrated by using both syngeneic and xenogeneic mouse models.

Downregulation of mitochondrial activity by immunosuppressive tumor-derived soluble factors leads to systemic unresponsiveness to the PD-1 blockade therapy.

The novel PDLIM2 nanomedicine enhances chemoimmunotherapy for complete cure of lung cancer.

SLAMF6 is an inhibitory checkpoint of T cells, the lack of which leads to better tumor control, suggesting a new immunotherapy target.

Knowledge graph identified an herbal drug combination for the treatment of plasma cell mastitis.

A study that models the evolution of drug resistance in tumors reveals that drugs are more effective when given in combination than sequentially, and that cure is much more likely when the drugs target different pathways.

ctDNA predict prognosis and treatment response of mTNBC patients more sensitively than traditional tumor markers, which implies ctDNA may be valuable for individualized treatment decision-making and paves the way for a non-invasive real-time clinical management strategy in patients with mTNBC.

Tumor immunogenicity is quantified with a novel method, and the resulting tumor immunogenicity score is an effective tumor-inherent biomarker for prediction of response to immune checkpoint inhibitors.